Alteogen

알테오젠 · 196170

Industrials Commercial Services · KOSDAQ

Large-cap

Market cap US$13.9B (₩19.1T)

Overview

Alteogen is a South Korean biotechnology company that develops drug technologies and biologic medicines.

It is best known for a platform that converts medicines given by intravenous infusion into versions that can be given as a quick under-the-skin injection, which it licenses to global drugmakers. The company also develops biosimilars and its own novel treatments. It earns money largely through licensing deals and related milestone payments.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$156.4M

▲ +109.9% YoY

Operating profit · FY2025

US$77.5M

▲ +320.8% YoY

Net income · FY2025

US$105.2M

▲ +139.2% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$69.9M(₩96.5B)	US$74.5M(₩102.9B)	US$156.4M(₩215.9B)
Operating profit	−US$7.1M(−₩9.7B)	US$18.4M(₩25.4B)	US$77.5M(₩106.9B)
Net income	−US$2.6M(−₩3.6B)	US$44M(₩60.7B)	US$105.2M(₩145.2B)

Revenue

FY2023US$69.9M
FY2024US$74.5M
FY2025US$156.4M

Operating profit

FY2023−US$7.1M
FY2024US$18.4M
FY2025US$77.5M

Net income

FY2023−US$2.6M
FY2024US$44M
FY2025US$105.2M

Key ratios (FY2025)

ROE

31.9%

Debt/Eq

53.8%

Op. margin

49.5%

Net margin

67.3%

Rev. YoY

▲ +109.9%

Why it matters

Much of its value rests on licensing its injection-technology platform to large pharmaceutical companies.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?